Defining the relationship between pain intensity and disease activity in patients with rheumatoid arthritis: a secondary analysis of six studies

[11] Eberhardt E(2013)Performance of the Dutch SF-36 version 2 as a measure of health-related quality of life in patients with rheumatoid arthritis Health Qual Life Outcomes 11 77-2429

[12] Wolfe F(2014)Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs Arthritis Res Ther 16 R56-663

[13] Schwartzman S(2011)Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study Arthritis Res Ther 13 R83-93

[14] Furfaro N(1973)Rheumatoid arthritis, typus robustus Ann Rheum Dis 32 91-1190

[15] Kavanaugh A(2019)TITRATE Programme Investigators. The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life Semin Arthritis Rheum 49 20-2014

[16] Heiberg T(2019)Investigating intraindividual pain variability: methods, applications, issues, and directions Pain 160 2415-310

[17] Kvien TK(2008)CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arhritis) Trial Group. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis Ann Rheum Dis 67 656-282

[18] Smolen JS(2016)A randomised trial evaluating anakinra in early active rheumatoid arthritis Clin Exp Rheumatol 34 88-2550

[19] Landewé RBM(2015)Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial BMJ 350 1182-592

[20] Bijlsma JWJ(2020)The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial Semin Arthritis Rheum 50 2004-1249

[11] Eberhardt E(2013)Performance of the Dutch SF-36 version 2 as a measure of health-related quality of life in patients with rheumatoid arthritis Health Qual Life Outcomes 11 77-2429

[12] Wolfe F(2014)Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs Arthritis Res Ther 16 R56-663

[13] Schwartzman S(2011)Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study Arthritis Res Ther 13 R83-93

[14] Furfaro N(1973)Rheumatoid arthritis, typus robustus Ann Rheum Dis 32 91-1190

[15] Kavanaugh A(2019)TITRATE Programme Investigators. The frequency of remission and low disease activity in patients with rheumatoid arthritis, and their ability to identify people with low disability and normal quality of life Semin Arthritis Rheum 49 20-2014

[16] Heiberg T(2019)Investigating intraindividual pain variability: methods, applications, issues, and directions Pain 160 2415-310

[17] Kvien TK(2008)CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arhritis) Trial Group. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis Ann Rheum Dis 67 656-282

[18] Smolen JS(2016)A randomised trial evaluating anakinra in early active rheumatoid arthritis Clin Exp Rheumatol 34 88-2550

[19] Landewé RBM(2015)Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial BMJ 350 1182-592

[20] Bijlsma JWJ(2020)The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trial Semin Arthritis Rheum 50 2004-1249